Translational implications of novel findings in cancer cachexia: The use of metabolomics and the potential of cardiac malfunction

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 4, 2012, Pages 446-450

  Der Torossian, Hirak ^a,b   Gourin, Christine G ^b   Couch, Marion E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cachexia; Cancer; Cardiac muscle; Metabolomics; Translational

Indexed keywords

ANIMAL; CACHEXIA; CARDIOMYOPATHY; DISEASE MODEL; HUMAN; METABOLISM; METABOLOMICS; MOUSE; NEOPLASM; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; CACHEXIA; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; HUMANS; METABOLOMICS; MICE; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84871251609     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328359b695     Document Type: Review

References (43)

1. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862-871.
2. Lawton KA, Berger A, Mitchell M, et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 2008; 9:383-397.
3. Argiles JM, Lopez-Soriano FJ, Busquets S. Mechanisms and treatment of cancer cachexia. Nutr Metab Cardiovasc Dis 2012. [Epub ahead of print]
4. Mantovani G, Maccio A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med 2010; 88:85-92.
5. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol 2010; 26:146-151.
6. Campos MP, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a review. Rev Assoc Med Bras 2011; 57:211-219.
7. Mock V, Atkinson A, Barsevick AM, et al. Cancer-related fatigue. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5:1054-1078.
8. Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995; 75:2613-2622.
9. Mortimer JE, Barsevick AM, Bennett CL, et al. Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw 2010; 8:1331-1339.
10. Horneber M, Fischer I, Dimeo F, et al. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int 2012; 109:161-171.
11. Schunemann M, Anker SD, Rauchhaus M. Cancer fatigue syndrome reflects clinically nonovert heart failure: an approach towards onco-cardiology. Nat Clin Pract Oncol 2008; 5:632-633.
12. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799.
13. Strasser F. Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue. Curr Opin Clin Nutr Metab Care 2008; 11:417-421.
14. Bennani-Baiti N, Walsh D. What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb 2009; 39:257-262.
15. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142:531-543.
16. Marin-Corral J, Fontes CC, Pascual-Guardia S, et al. Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. Antioxid Redox Signal 2010; 12:365-380.
17. Drott C, Ekman L, Holm S, et al. Effects of tumor-load and malnutrition on myocardial function in the isolated working rat heart. J Mol Cell Cardiol 1986; 18:1165-1176.
18. Drott C, Waldenstrom A, Lundholm K. Cardiac sensitivity and responsiveness to beta-Adrenergic stimulation in experimental cancer and undernutrition. J Mol Cell Cardiol 1987; 19:675-683.
19. Sjostrom M, Wretling ML, Karlberg I, et al. Ultrastructural changes and enzyme activities for energy production in hearts concomitant with tumor-Associated malnutrition. J Surg Res 1987; 42:304-313.
20. Tian M, Nishijima Y, Asp ML, et al. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol 2010; 37:347-353.
21. Burch GE, Phillips JH, Ansari A. The cachectic heart. A clinico-pathologic, electrocardiographic and roentgenographic entity. Dis Chest 1968; 54:403-409; Epub 1968/11/01.
22. Shadfar S, Couch M, McKinney K, Weinstein L, Yin X, Rodríguez J, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer 2011; 63:749-762.
23. Wysong A, Couch M, Shadfar S, et al. NF-kB inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol 2011; 178:1059-1068.
24. Cosper PF, Leinwand LA. Cancer Causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res 2011; 71:1710-1720.
25. Hellerstein HK, Santiago-Stevenson D. Atrophy of the Heart: a correlative study of eighty-five proved cases. Circulation 1950; 1:93-126.
26. von Haehling S, editor. Cardiac alterations in cancer cachexia. In: Proceedings of the 5th Cachexia Conference; December 2009; Barcelona, Spain.
27. Costelli P, Carbo N, Tessitore L, et al. Tumor necrosis factor-Alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993; 92:2783-2789.
28. Costelli P, Tullio RD, Baccino FM, Melloni E. Activation of Ca(2\+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer 2001; 84:946-950.
29. Tessitore L, Costelli P, Bonetti G, Baccino FM. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 1993; 306:52-58.
30. Lundholm K, Edstrom S, Ekman L, et al. A comparative study of the influence of malignant tumor on host metabolism in mice and man: evaluation of an experimental model. Cancer 1978; 42:453-461.
31. Xu H, Crawford D, Hutchinson KR, et al. Myocardial dysfunction in an animal model of cancer cachexia. Life Sci 2010; 88:406-410.
32. Drott C, Lundholm K. Glucose uptake and amino acid metabolism in perfused hearts from tumor-bearing rats. J Surg Res 1990; 49:62-68.
33. Kumar NB, Kazi A, Smith T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010; 11 (3-4):107-117.
34. Tardiff JC, Hewett TE, Factor SM, et al. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 2000; 278:H412-H419.
35. Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol 2011; 39: 1321-1326.
36. El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008; 14:61-74.
37. Springer J, Hartmann A, Palus S, et al. Development of severe progressive heart failure in experimental cancer cachexia. In: Proceedings of the 13th Annual Scientific Meeting of Heart Failure Society of America; September 2009; Boston, Massachusetts.
38. Springer J, Tschirner A, Palus S, et al. Severe progressive heart failure in experimental cancer cachexia only transiently elevates B-type natriuretic peptide (BNP). In: Proceedings of the 5th Cachexia Conference; December 2009; Barcelona, Spain.
39. Bennani-Baiti N, Walsh D. Animal models of the cancer anorexia-cachexia syndrome. Support Care Cancer 2011; 19:1451-1463.
40. McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007; 28:829-835.
41. Florea VG, Henein MY, Rauchhaus M, et al. The cardiac component of cardiac cachexia. Am Heart J 2002; 144:45-50.
42. Florea VG, Moon J, Pennell DJ, et al. Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. Int J Cardiol 2004; 97:15-20.
43. O'Connell T, Ardeshirpour F, Asher S, et al. Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics 2008; 4:216-225.